Stockreport

Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race [Seeking Alpha]

Century Therapeutics, Inc.  (IPSC) 
PDF cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived ß-cell therapy, CNTY-813. IPSC's Allo-Evasion platform uniquely targets T-cell, NK-cell, and [Read more]